Fig. 1: PRSS22 is highly expressed in CRC and associated with poor prognosis. | Oncogene

Fig. 1: PRSS22 is highly expressed in CRC and associated with poor prognosis.

From: PRSS22 inhibits HMOX1-mediated ferroptosis and induces osteopontin cleavage to promote M2 macrophage polarization and colitis-associated carcinogenesis

Fig. 1: PRSS22 is highly expressed in CRC and associated with poor prognosis.

A Workflow illustrating the strategy of identifying core differentially expressed genes (DEGs) between tumour and normal tissues in the TCGA CRC cohort and in a murine CAC model [14, 23]. B Bar plot showing the top overlapping upregulated genes identified in the two models from (A). C mRNA expression levels of PDIAs in primary colon (n = 473) and rectal (n = 167) tumours compared with their respective benign tissues (n = 41 for colon; and n = 10 for rectal). Groups were compared using two-way ANOVA and Sidak’s multiple comparison tests. D Expression levels of PRSS22 in metastatic (MET) (n = 94) versus primary CRC (PT) (n = 39) from GSE41568 [15]. Groups were compared using unpaired t tests. E Kaplan–Meier curves for overall survival (OS) with high (n = 443) and low PRSS22 expression (n = 618) patient cohorts. F Kaplan–Meier curves for recurrence-free survival (RFS) with high (n = 883) and low PRSS22 expression (n = 453) patient cohorts. G, H ROC curve analyses of PRSS22 in colon (AUC = 0.983) and rectal (AUC = 0.919) cancers. I Analysis of a Spatially-resolved CRC primary tumour samples transcriptomic profile dataset illustrating spatial distribution of PRSS22 and the CRC marker CEACAM6 [11]. In all panels: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page